Depakote
Depakote News
Contact a Depakote Lawyer
March 15th, 2004
"Depakote Risks Must Be Adequately Assessed"
Depakote is currently the mot prescribed branded treatment for patients with mania associated with bipolar disorder and the most prescribed branded treatment for epilepsy. Made by Abbott Laboratories, the company just had a victory after proving a generic product was infringing on Abbott patents for Depakote.
There are deadly risks associated to the use of Depakote. Especially patients with hepatic disease or significant hepatic dysfunction should avoid the use of Depakote as hepatic failure resulting in death has occurred among Depakote users. Tetratogenic effects in babies of women using Depakote indicate childbearing women must fully consider the potential risk of using the drug. Fatal instances of pancereatitis have been suffered in adult and children Depakote patients.
Safety and efficacy of Depakote and Depakote ER for migraine prevention in patients over 65 has never been established. Amongst pediatric patients, the safety and efficacy of Depakote ER has not been established for the prophylaxis of migraine headaches as well as for the treatment of epilepsy in pediatric patients under the age of 10.
